Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Inhibrx Biosciences (INBX) over the last 2 years, with Sep 2025 value amounting to -$1.5 million.

  • Inhibrx Biosciences' Change in Account Payables fell 237.56% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.6 million, marking a year-over-year decrease of 123.36%. This contributed to the annual value of $17.9 million for FY2024, which is 748.89% up from last year.
  • According to the latest figures from Q3 2025, Inhibrx Biosciences' Change in Account Payables is -$1.5 million, which was down 153.17% from -$600,000 recorded in Q2 2025.
  • In the past 5 years, Inhibrx Biosciences' Change in Account Payables ranged from a high of $17.4 million in Q2 2024 and a low of -$3.1 million during Q4 2024.
  • Its 3-year average for Change in Account Payables is $1.9 million, with a median of -$450,000 in 2024.
  • In the last 5 years, Inhibrx Biosciences' Change in Account Payables soared by 71.75% in 2024 and then tumbled by 237.56% in 2025.
  • Quarterly analysis of 3 years shows Inhibrx Biosciences' Change in Account Payables stood at $2.9 million in 2023, then slumped by 207.18% to -$3.1 million in 2024, then slumped by 237.56% to -$1.5 million in 2025.
  • Its Change in Account Payables stands at -$1.5 million for Q3 2025, versus -$600,000 for Q2 2025 and -$353,000 for Q1 2025.